Vanguard Global Advisers
TBPH icon

Vanguard Global Advisers’s Theravance Biopharma TBPH Stock Holding History

Vanguard Global Advisers’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$252K Sell
14,832
-3,013
-17% -$49.9K ﹤0.01% 2407
2026
Q1 		$290K Buy
+17,845
New +$316K ﹤0.01% 2262

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Global Advisers's TBPH Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Theravance Biopharma (TBPH) stake by 17% in Q2 2026, selling an estimated $49.9K and leaving 14,832 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Vanguard Global Advisers first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. The position peaked at $290K in Q1 2026. 177 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Vanguard Global Advisers held 14,832 shares of Theravance Biopharma worth $252K as of Q2 2026.
  • Vanguard Global Advisers sold 3,013 Theravance Biopharma shares in Q2 2026, an estimated $49.9K.
  • Theravance Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2407 holding.
  • Vanguard Global Advisers first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Theravance Biopharma position peaked at $290K in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.